Symbols / KPRX $2.02 +5.21% Kiora Pharmaceuticals, Inc.
KPRX Chart
About
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.98M |
| Enterprise Value | -9.06M | Income | -10.84M | Sales | — |
| Book/sh | 4.29 | Cash/sh | 4.33 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.91 | PEG | — |
| P/S | — | P/B | 0.47 | P/C | — |
| EV/EBITDA | 0.96 | EV/Sales | — | Quick Ratio | 5.62 |
| Current Ratio | 5.99 | Debt/Eq | 2.28 | LT Debt/Eq | — |
| EPS (ttm) | -2.64 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-25 07:00 | ROA | -19.47% |
| ROE | -51.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.95M |
| Shs Float | 3.81M | Short Float | 0.43% | Short Ratio | 0.67 |
| Short Interest | — | 52W High | 4.18 | 52W Low | 1.76 |
| Beta | -0.77 | Avg Volume | 47.62K | Volume | 11.06K |
| Target Price | $12.00 | Recom | Buy | Prev Close | $1.92 |
| Price | $2.02 | Change | 5.21% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-23 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-20 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-02-09 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-24 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-14 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-09 | main | Maxim Group | Buy → Buy | $2 |
| 2023-05-12 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-24 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2023-02-09 | up | Maxim Group | Hold → Buy | $12 |
| 2023-02-08 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-02-08 | reit | Ladenburg Thalmann | — → Buy | $119 |
- Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan hu, 02 Apr 2026 20
- KPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Wed, 01 Apr 2026 09
- Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan hu, 02 Apr 2026 20
- Kiora Pharmaceuticals Announces Chief Development Officer Resignation - tipranks.com hu, 02 Apr 2026 21
- Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan hu, 02 Apr 2026 20
- Maxim Group Maintains Kiora Pharmaceuticals(KPRX.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛 Fri, 27 Mar 2026 07
- symbol__ Stock Quote Price and Forecast - CNN Mon, 12 Feb 2024 02
- Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) - intelligentinvestor.com.au hu, 07 Aug 2025 02
- Kiora Pharmaceuticals inks potential $110 million deal with Senju - Investing.com ue, 03 Jun 2025 07
- Karyopharm Therapeutics (KPRX): Tiny Cancer Stock, Massive Drama – Is It Worth Your Money? - AD HOC NEWS Sat, 07 Feb 2026 08
- Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan hu, 02 Apr 2026 20
- We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance Fri, 15 Nov 2024 08
- Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan hu, 02 Apr 2026 20
- If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan Sun, 22 Mar 2026 16
- Two retinal disease trials underway as Kiora says cash lasts into 2027 - Stock Titan Wed, 25 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
16.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
-100.00%
|
16.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.46
-9.21%
|
10.42
+19.90%
|
8.69
-25.90%
|
11.73
|
| Research And Development |
|
3.71
-24.15%
|
4.90
+21.60%
|
4.03
+16.76%
|
3.45
|
| Selling General And Administration |
|
5.75
+3.66%
|
5.54
+18.85%
|
4.66
-43.67%
|
8.28
|
| General And Administrative Expense |
|
5.75
+3.66%
|
5.54
+18.85%
|
4.66
-43.67%
|
8.28
|
| Other Gand A |
|
5.75
+3.66%
|
5.54
+18.85%
|
4.66
-43.67%
|
8.28
|
| Other Operating Expenses |
|
—
|
-0.02
|
—
|
—
|
| Total Expenses |
|
9.46
-9.21%
|
10.42
+19.90%
|
8.69
-25.90%
|
11.73
|
| Operating Income |
|
-9.46
-269.50%
|
5.58
+164.22%
|
-8.69
+25.90%
|
-11.73
|
| Total Operating Income As Reported |
|
-12.83
-384.48%
|
4.51
+135.83%
|
-12.59
-2.25%
|
-12.31
|
| EBITDA |
|
-12.07
-311.78%
|
5.70
+146.12%
|
-12.36
+9.42%
|
-13.65
|
| Normalized EBITDA |
|
-8.70
-226.48%
|
6.88
+181.55%
|
-8.44
+27.55%
|
-11.64
|
| Reconciled Depreciation |
|
0.02
+29.14%
|
0.02
-62.92%
|
0.05
+24.49%
|
0.04
|
| EBIT |
|
-12.10
-312.94%
|
5.68
+145.77%
|
-12.41
+9.32%
|
-13.69
|
| Total Unusual Items |
|
-3.37
-186.10%
|
-1.18
+69.97%
|
-3.93
-95.91%
|
-2.00
|
| Total Unusual Items Excluding Goodwill |
|
-3.37
-186.10%
|
-1.18
+69.97%
|
-3.93
-95.91%
|
-2.00
|
| Special Income Charges |
|
-3.37
-186.10%
|
-1.18
+69.97%
|
-3.93
-578.62%
|
-0.58
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
0.10
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
-1.25
-33.57%
|
-0.94
-147.05%
|
1.99
+241.98%
|
0.58
|
| Write Off |
|
4.62
+130.28%
|
2.01
+5.44%
|
1.90
|
0.00
|
| Net Income |
|
-10.84
-401.42%
|
3.59
+128.73%
|
-12.51
+7.88%
|
-13.58
|
| Pretax Income |
|
-12.12
-314.10%
|
5.66
+145.56%
|
-12.42
+9.29%
|
-13.70
|
| Net Non Operating Interest Income Expense |
|
0.87
-29.02%
|
1.23
+656.13%
|
0.16
+237.23%
|
0.05
|
| Interest Expense Non Operating |
|
0.02
-6.93%
|
0.02
+92.65%
|
0.01
+29.46%
|
0.01
|
| Net Interest Income |
|
0.87
-29.02%
|
1.23
+656.13%
|
0.16
+237.23%
|
0.05
|
| Interest Expense |
|
0.02
-6.93%
|
0.02
+92.65%
|
0.01
+29.46%
|
0.01
|
| Interest Income Non Operating |
|
0.89
-28.64%
|
1.25
+620.07%
|
0.17
+205.83%
|
0.06
|
| Interest Income |
|
0.89
-28.64%
|
1.25
+620.07%
|
0.17
+205.83%
|
0.06
|
| Other Income Expense |
|
-3.53
-206.48%
|
-1.15
+70.42%
|
-3.90
-93.08%
|
-2.02
|
| Other Non Operating Income Expenses |
|
-0.16
-714.70%
|
0.03
-9.60%
|
0.03
+298.93%
|
-0.01
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
-1.43
|
| Gain On Sale Of Business |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
-1.28
-162.09%
|
2.07
+2186.35%
|
0.09
+179.92%
|
-0.11
|
| Tax Rate For Calcs |
|
0.00
-71.00%
|
0.00
+73.74%
|
0.00
+636.84%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.36
+17.03%
|
-0.43
+47.83%
|
-0.82
-1343.56%
|
-0.06
|
| Net Income Including Noncontrolling Interests |
|
-10.84
-401.42%
|
3.59
+128.73%
|
-12.51
+7.88%
|
-13.58
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.84
-401.42%
|
3.59
+128.73%
|
-12.51
+7.88%
|
-13.58
|
| Net Income From Continuing And Discontinued Operation |
|
-10.84
-401.42%
|
3.59
+128.73%
|
-12.51
+7.88%
|
-13.58
|
| Net Income Continuous Operations |
|
-10.84
-401.42%
|
3.59
+128.73%
|
-12.51
+7.88%
|
-13.58
|
| Normalized Income |
|
-7.82
-280.05%
|
4.34
+146.14%
|
-9.41
+19.11%
|
-11.64
|
| Net Income Common Stockholders |
|
-10.84
-401.42%
|
3.59
+127.56%
|
-13.04
+3.97%
|
-13.58
|
| Otherunder Preferred Stock Dividend |
|
—
|
0.00
-100.00%
|
0.53
|
0.00
|
| Diluted EPS |
|
—
|
0.87
+103.59%
|
-24.25
+85.47%
|
-166.95
|
| Basic EPS |
|
—
|
0.93
+103.84%
|
-24.25
+85.47%
|
-166.95
|
| Basic Average Shares |
|
—
|
3.87
+619.81%
|
0.54
+561.22%
|
0.08
|
| Diluted Average Shares |
|
—
|
4.13
+666.73%
|
0.54
+561.22%
|
0.08
|
| Diluted NI Availto Com Stockholders |
|
-10.84
-401.42%
|
3.59
+127.56%
|
-13.04
+3.97%
|
-13.58
|
| Gain On Sale Of PPE |
|
0.00
+100.00%
|
-0.00
+86.40%
|
-0.03
-773.93%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
24.25
-33.52%
|
36.48
+166.08%
|
13.71
-26.59%
|
18.68
|
| Current Assets |
|
21.75
-26.79%
|
29.71
+526.97%
|
4.74
-38.31%
|
7.68
|
| Cash Cash Equivalents And Short Term Investments |
|
17.09
-36.22%
|
26.79
+991.47%
|
2.45
-58.85%
|
5.96
|
| Cash And Cash Equivalents |
|
8.70
+129.32%
|
3.79
+54.49%
|
2.45
-58.85%
|
5.96
|
| Other Short Term Investments |
|
8.39
-63.51%
|
23.00
|
0.00
|
—
|
| Receivables |
|
3.32
+280.54%
|
0.87
-57.49%
|
2.05
+49.30%
|
1.37
|
| Other Receivables |
|
1.52
+153.29%
|
0.60
|
—
|
—
|
| Taxes Receivable |
|
1.79
+563.64%
|
0.27
-86.82%
|
2.05
+49.30%
|
1.37
|
| Prepaid Assets |
|
0.20
|
0.00
|
—
|
—
|
| Other Current Assets |
|
1.14
-44.10%
|
2.04
+775.17%
|
0.23
-31.97%
|
0.34
|
| Total Non Current Assets |
|
2.50
-63.05%
|
6.78
-24.46%
|
8.97
-18.40%
|
11.00
|
| Net PPE |
|
0.38
+504.95%
|
0.06
-45.72%
|
0.11
-33.23%
|
0.17
|
| Gross PPE |
|
0.40
+536.03%
|
0.06
-47.69%
|
0.12
-58.12%
|
0.29
|
| Accumulated Depreciation |
|
-0.03
-2430.47%
|
-0.00
+83.72%
|
-0.01
+94.64%
|
-0.12
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.01
+8.62%
|
0.01
+148.16%
|
0.00
-95.90%
|
0.06
|
| Other Properties |
|
0.29
+399.96%
|
0.06
-51.85%
|
0.12
-42.20%
|
0.21
|
| Leases |
|
0.11
|
0.00
|
0.00
-100.00%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
2.06
-69.15%
|
6.69
-24.13%
|
8.81
-17.96%
|
10.74
|
| Goodwill |
|
—
|
—
|
—
|
—
|
| Other Intangible Assets |
|
2.06
-69.15%
|
6.69
-24.13%
|
8.81
-17.96%
|
10.74
|
| Other Non Current Assets |
|
0.06
+121.79%
|
0.03
-35.67%
|
0.05
-45.25%
|
0.08
|
| Total Liabilities Net Minority Interest |
|
8.13
-24.22%
|
10.72
+41.07%
|
7.60
+4.56%
|
7.27
|
| Current Liabilities |
|
3.63
-39.56%
|
6.01
+267.73%
|
1.63
-50.07%
|
3.27
|
| Payables And Accrued Expenses |
|
3.47
-42.07%
|
5.99
+277.17%
|
1.59
-44.20%
|
2.84
|
| Payables |
|
1.20
-56.17%
|
2.74
+1230.18%
|
0.21
-79.54%
|
1.01
|
| Accounts Payable |
|
1.06
+155.13%
|
0.42
+101.49%
|
0.21
-79.54%
|
1.01
|
| Current Accrued Expenses |
|
2.26
-30.14%
|
3.24
+134.79%
|
1.38
-24.80%
|
1.84
|
| Total Tax Payable |
|
0.14
-93.90%
|
2.33
|
0.00
|
—
|
| Income Tax Payable |
|
0.14
-93.90%
|
2.33
|
0.00
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.16
+604.18%
|
0.02
-50.38%
|
0.05
-55.50%
|
0.11
|
| Current Capital Lease Obligation |
|
0.16
+604.18%
|
0.02
-50.38%
|
0.05
-55.50%
|
0.11
|
| Other Current Liabilities |
|
—
|
—
|
—
|
0.32
|
| Total Non Current Liabilities Net Minority Interest |
|
4.50
-4.68%
|
4.72
-20.98%
|
5.97
+49.27%
|
4.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.20
+502.69%
|
0.03
-43.47%
|
0.06
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.20
+502.69%
|
0.03
-43.47%
|
0.06
|
0.00
|
| Non Current Deferred Liabilities |
|
1.35
+175.56%
|
0.49
-37.05%
|
0.78
+13.11%
|
0.69
|
| Non Current Deferred Revenue |
|
1.25
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
0.10
-79.18%
|
0.49
-37.05%
|
0.78
+13.11%
|
0.69
|
| Other Non Current Liabilities |
|
2.94
-29.87%
|
4.19
-18.28%
|
5.13
+54.99%
|
3.31
|
| Stockholders Equity |
|
16.13
-37.40%
|
25.76
+321.62%
|
6.11
-46.44%
|
11.41
|
| Common Stock Equity |
|
16.13
-37.40%
|
25.76
+321.62%
|
6.11
-46.44%
|
11.41
|
| Capital Stock |
|
0.28
+2.84%
|
0.27
+247.27%
|
0.08
+328.57%
|
0.02
|
| Common Stock |
|
0.28
+2.84%
|
0.27
+247.28%
|
0.08
+328.54%
|
0.02
|
| Preferred Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Share Issued |
|
3.76
+25.36%
|
3.00
+250.48%
|
0.86
+328.93%
|
0.20
|
| Ordinary Shares Number |
|
3.76
+25.36%
|
3.00
+250.48%
|
0.86
+328.93%
|
0.20
|
| Additional Paid In Capital |
|
170.31
+0.68%
|
169.16
+10.42%
|
153.19
+4.90%
|
146.04
|
| Retained Earnings |
|
-154.22
-7.56%
|
-143.38
+2.45%
|
-146.98
-9.31%
|
-134.46
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.25
+12.77%
|
-0.28
-54.35%
|
-0.18
-0.03%
|
-0.18
|
| Other Equity Adjustments |
|
-0.25
+12.77%
|
-0.28
-54.35%
|
-0.18
-0.03%
|
-0.18
|
| Total Equity Gross Minority Interest |
|
16.13
-37.40%
|
25.76
+321.62%
|
6.11
-46.44%
|
11.41
|
| Total Capitalization |
|
16.13
-37.40%
|
25.76
+321.62%
|
6.11
-46.44%
|
11.41
|
| Working Capital |
|
18.12
-23.55%
|
23.70
+663.44%
|
3.10
-29.59%
|
4.41
|
| Invested Capital |
|
16.13
-37.40%
|
25.76
+321.62%
|
6.11
-46.44%
|
11.41
|
| Total Debt |
|
0.37
+544.15%
|
0.06
-46.52%
|
0.11
+1.05%
|
0.11
|
| Capital Lease Obligations |
|
0.37
+544.15%
|
0.06
-46.52%
|
0.11
+1.05%
|
0.11
|
| Net Tangible Assets |
|
14.06
-26.26%
|
19.07
+805.30%
|
-2.70
-506.99%
|
0.66
|
| Tangible Book Value |
|
14.06
-26.26%
|
19.07
+805.30%
|
-2.70
-506.99%
|
0.66
|
| Preferred Stock Equity |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-9.96
-216.38%
|
8.56
+189.56%
|
-9.56
+8.35%
|
-10.43
|
| Cash Flow From Continuing Operating Activities |
|
-9.96
-216.38%
|
8.56
+189.56%
|
-9.56
+8.35%
|
-10.43
|
| Net Income From Continuing Operations |
|
-10.84
-401.42%
|
3.59
+128.73%
|
-12.51
+7.88%
|
-13.58
|
| Depreciation Amortization Depletion |
|
0.02
+29.14%
|
0.02
-62.92%
|
0.05
+24.49%
|
0.04
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Amortization Cash Flow |
|
0.02
+29.14%
|
0.02
-62.92%
|
0.05
|
—
|
| Depreciation And Amortization |
|
0.02
+29.14%
|
0.02
-62.92%
|
0.05
+24.49%
|
0.04
|
| Amortization Of Intangibles |
|
0.02
+29.14%
|
0.02
-62.92%
|
0.05
|
—
|
| Other Non Cash Items |
|
-0.90
+1.68%
|
-0.92
-145.77%
|
2.00
+196.73%
|
0.68
|
| Stock Based Compensation |
|
0.90
+37.11%
|
0.66
-13.03%
|
0.75
+63.25%
|
0.46
|
| Asset Impairment Charge |
|
4.62
+118.92%
|
2.11
+10.91%
|
1.90
|
0.00
|
| Deferred Tax |
|
-0.39
-34.56%
|
-0.29
-419.70%
|
0.09
+179.92%
|
-0.11
|
| Deferred Income Tax |
|
-0.39
-34.56%
|
-0.29
-419.70%
|
0.09
+179.92%
|
-0.11
|
| Operating Gains Losses |
|
-0.00
-212.38%
|
-0.00
+97.02%
|
-0.03
-101.79%
|
1.42
|
| Gain Loss On Investment Securities |
|
-0.00
+47.53%
|
-0.00
|
—
|
1.43
|
| Unrealized Gain Loss On Investment Securities |
|
-0.00
-200.00%
|
0.00
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.00
-86.75%
|
0.03
+773.93%
|
-0.00
|
| Change In Working Capital |
|
-3.27
-189.21%
|
3.67
+301.22%
|
-1.82
-372.54%
|
0.67
|
| Change In Receivables |
|
-2.41
-333.71%
|
1.03
+288.51%
|
-0.55
+37.20%
|
-0.87
|
| Change In Prepaid Assets |
|
0.42
+123.01%
|
-1.82
-206190.06%
|
0.00
-99.68%
|
0.28
|
| Change In Payables And Accrued Expense |
|
-2.39
-153.19%
|
4.49
+454.02%
|
-1.27
-191.06%
|
1.39
|
| Change In Accrued Expense |
|
-3.51
-182.41%
|
4.26
+1027.07%
|
-0.46
-175.40%
|
0.61
|
| Change In Payable |
|
1.12
+397.49%
|
0.23
+127.98%
|
-0.81
-203.27%
|
0.78
|
| Change In Account Payable |
|
1.12
+397.49%
|
0.23
+127.98%
|
-0.81
-203.27%
|
0.78
|
| Change In Other Working Capital |
|
1.25
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
-0.03
-324.36%
|
0.02
+300.86%
|
-0.01
+66.25%
|
-0.02
|
| Change In Other Current Liabilities |
|
-0.10
-123.32%
|
-0.05
-8062.33%
|
0.00
+100.56%
|
-0.10
|
| Investing Cash Flow |
|
14.43
+163.66%
|
-22.66
|
0.00
-100.00%
|
0.01
|
| Cash Flow From Continuing Investing Activities |
|
14.43
+163.66%
|
-22.66
|
0.00
-100.00%
|
0.01
|
| Net PPE Purchase And Sale |
|
-0.11
-1670.92%
|
-0.01
|
0.00
-100.00%
|
0.01
|
| Purchase Of PPE |
|
-0.11
-1670.92%
|
-0.01
|
0.00
|
0.00
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Capital Expenditure |
|
-0.11
-1670.92%
|
-0.01
|
—
|
—
|
| Net Investment Purchase And Sale |
|
14.54
+164.16%
|
-22.66
|
0.00
|
—
|
| Purchase Of Investment |
|
-8.18
+77.05%
|
-35.63
|
0.00
|
—
|
| Sale Of Investment |
|
22.71
+75.04%
|
12.98
|
0.00
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
—
|
0.00
|
| Gain Loss On Sale Of Business |
|
—
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Financing Cash Flow |
|
0.27
-98.29%
|
15.50
+159.77%
|
5.97
-30.80%
|
8.62
|
| Cash Flow From Continuing Financing Activities |
|
0.27
-98.29%
|
15.50
+159.77%
|
5.97
-30.80%
|
8.62
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
|
—
|
0.00
|
| Issuance Of Debt |
|
2.75
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
-2.75
|
0.00
|
—
|
0.00
|
| Long Term Debt Issuance |
|
2.75
|
0.00
|
—
|
—
|
| Long Term Debt Payments |
|
-2.75
|
0.00
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
|
0.00
|
—
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
15.00
+115.27%
|
6.97
+29.94%
|
5.36
|
| Common Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Proceeds From Stock Option Exercised |
|
0.27
-84.27%
|
1.69
+450.13%
|
0.31
-90.58%
|
3.26
|
| Net Other Financing Charges |
|
—
|
-1.19
+9.04%
|
-1.31
|
—
|
| Changes In Cash |
|
4.73
+239.23%
|
1.39
+138.84%
|
-3.59
-99.40%
|
-1.80
|
| Effect Of Exchange Rate Changes |
|
0.17
+403.39%
|
-0.06
-258.89%
|
0.04
+142.36%
|
-0.09
|
| Beginning Cash Position |
|
3.80
+54.39%
|
2.46
-59.11%
|
6.01
-23.87%
|
7.90
|
| End Cash Position |
|
8.70
+129.20%
|
3.80
+54.39%
|
2.46
-59.11%
|
6.01
|
| Free Cash Flow |
|
-10.07
-217.76%
|
8.55
+189.49%
|
-9.56
+8.35%
|
-10.43
|
| Amortization Of Securities |
|
-0.11
+60.38%
|
-0.28
|
0.00
|
—
|
| Common Stock Issuance |
|
0.00
-100.00%
|
15.00
+115.27%
|
6.97
+29.56%
|
5.38
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
15.00
+115.27%
|
6.97
+29.56%
|
5.38
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 8-K2026-04-02 View
- 8-K2026-03-25 View
- 10-K2026-03-25 View
- 42026-03-10 View
- 42026-03-10 View
- 42026-03-10 View
- 42026-03-06 View
- 42026-03-06 View
- 8-K2025-11-07 View
- 10-Q2025-11-07 View
- 8-K2025-08-13 View
- 8-K2025-08-08 View
- 10-Q2025-08-08 View
- 8-K2025-06-04 View
- 8-K2025-06-03 View
- 8-K2025-05-09 View
- 10-Q2025-05-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|